223 related articles for article (PubMed ID: 9252959)
1. Characterization of an HL-60 cell variant resistant to the antineoplastic ether lipid 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine.
Small GW; Strum JC; Daniel LW
Lipids; 1997 Jul; 32(7):715-23. PubMed ID: 9252959
[TBL] [Abstract][Full Text] [Related]
2. Quaternary ammonium analogs of ether lipids inhibit the activation of protein kinase C and the growth of human leukemia cell lines.
Civoli F; Daniel LW
Cancer Chemother Pharmacol; 1998; 42(4):319-26. PubMed ID: 9744778
[TBL] [Abstract][Full Text] [Related]
3. Correlation of ether lipid content of human leukemia cell lines and their susceptibility to 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine.
Chabot MC; Wykle RL; Modest EJ; Daniel LW
Cancer Res; 1989 Aug; 49(16):4441-5. PubMed ID: 2743333
[TBL] [Abstract][Full Text] [Related]
4. Sensitivity of K562 and HL-60 cells to edelfosine, an ether lipid drug, correlates with production of reactive oxygen species.
Wagner BA; Buettner GR; Oberley LW; Burns CP
Cancer Res; 1998 Jul; 58(13):2809-16. PubMed ID: 9661895
[TBL] [Abstract][Full Text] [Related]
5. Differentiation of HL-60 cells distinguishes between cytostatic and cytotoxic effects of the alkylphospholipid ET-18-OCH3.
Civoli F; Pauig SB; Daniel LW
Cancer Chemother Pharmacol; 1996; 38(3):269-72. PubMed ID: 8646802
[TBL] [Abstract][Full Text] [Related]
6. Undifferentiated HL-60 cells internalize an antitumor alkyl ether phospholipid more rapidly than resistant K562 cells.
Tsutsumi T; Tokumura A; Kitazawa S
Biochim Biophys Acta; 1998 Feb; 1390(1):73-84. PubMed ID: 9487142
[TBL] [Abstract][Full Text] [Related]
7. Selective induction of apoptosis in cancer cells by the ether lipid ET-18-OCH3 (Edelfosine): molecular structure requirements, cellular uptake, and protection by Bcl-2 and Bcl-X(L).
Mollinedo F; Fernández-Luna JL; Gajate C; Martín-Martín B; Benito A; Martínez-Dalmau R; Modolell M
Cancer Res; 1997 Apr; 57(7):1320-8. PubMed ID: 9102220
[TBL] [Abstract][Full Text] [Related]
8. Protein kinase C is not involved in the cytotoxic action of 1-octadecyl-2-O-methyl-sn-glycerol-3-phosphocholine in HL-60 and K562 cells.
Heesbeen EC; Verdonck LF; Staal GE; Rijksen G
Biochem Pharmacol; 1994 Apr; 47(9):1481-8. PubMed ID: 8185658
[TBL] [Abstract][Full Text] [Related]
9. Involvement of c-Jun NH2-terminal kinase activation and c-Jun in the induction of apoptosis by the ether phospholipid 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine.
Gajate C; Santos-Beneit A; Modolell M; Mollinedo F
Mol Pharmacol; 1998 Apr; 53(4):602-12. PubMed ID: 9547349
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of growth factor-dependent inositol phosphate Ca2+ signaling by antitumor ether lipid analogues.
Seewald MJ; Olsen RA; Sehgal I; Melder DC; Modest EJ; Powis G
Cancer Res; 1990 Aug; 50(15):4458-63. PubMed ID: 2369723
[TBL] [Abstract][Full Text] [Related]
11. Membrane peroxidative damage enhancement by the ether lipid class of antineoplastic agents.
Wagner BA; Buettner GR; Burns CP
Cancer Res; 1992 Nov; 52(21):6045-51. PubMed ID: 1394229
[TBL] [Abstract][Full Text] [Related]
12. Selective inhibition of phosphatidylinositol phospholipase C by cytotoxic ether lipid analogues.
Powis G; Seewald MJ; Gratas C; Melder D; Riebow J; Modest EJ
Cancer Res; 1992 May; 52(10):2835-40. PubMed ID: 1316230
[TBL] [Abstract][Full Text] [Related]
13. The degradation of platelet-activating factor and related lipids: susceptibility to phospholipases C and D.
Wilcox RW; Wykle RL; Schmitt JD; Daniel LW
Lipids; 1987 Nov; 22(11):800-7. PubMed ID: 3444369
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of calcium-dependent protein kinase C by hexadecylphosphocholine and 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine do not correlate with inhibition of proliferation of HL60 and K562 cell lines.
Berkovic D; Berkovic K; Fleer EA; Eibl H; Unger C
Eur J Cancer; 1994; 30A(4):509-15. PubMed ID: 8018410
[TBL] [Abstract][Full Text] [Related]
15. Relationship of cell survival, drug dose, and drug uptake after 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine treatment.
Fujiwara K; Daniel LW; Modest EJ; Wallen CA
Cancer Chemother Pharmacol; 1994; 34(6):472-6. PubMed ID: 7923557
[TBL] [Abstract][Full Text] [Related]
16. Increased membrane permeability for an antitumoral alkyl lysophospholipid in sensitive tumor cells.
Storch J; Munder PG
Lipids; 1987 Nov; 22(11):813-9. PubMed ID: 3444371
[TBL] [Abstract][Full Text] [Related]
17. Induction of apoptosis in human mitogen-activated peripheral blood T-lymphocytes by the ether phospholipid ET-18-OCH3: involvement of the Fas receptor/ligand system.
Cabaner C; Gajate C; Macho A; Muñoz E; Modolell M; Mollinedo F
Br J Pharmacol; 1999 Jun; 127(4):813-25. PubMed ID: 10433487
[TBL] [Abstract][Full Text] [Related]
18. Unidirectional membrane uptake of the ether lipid antineoplastic agent edelfosine by L1210 cells.
Kelley EE; Modest EJ; Burns CP
Biochem Pharmacol; 1993 Jun; 45(12):2435-9. PubMed ID: 8328981
[TBL] [Abstract][Full Text] [Related]
19. ET-18-OCH3 inhibits nuclear factor-kappa B activation by 12-O-tetradecanoylphorbol-13-acetate but not by tumor necrosis factor-alpha or interleukin 1 alpha.
Daniel LW; Civoli F; Rogers MA; Smitherman PK; Raju PA; Roederer M
Cancer Res; 1995 Nov; 55(21):4844-9. PubMed ID: 7585518
[TBL] [Abstract][Full Text] [Related]
20. Influence of serum levels on leukemic cell destruction by the ether lipid ET-18-OCH3.
Heesbeen EC; Rijksen G; van Heugten HG; Verdonck LF
Leuk Res; 1995 Jun; 19(6):417-25. PubMed ID: 7596155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
